AZN.UK

10,326

-0.41%↓

GSK

1,423.5

+0.04%↑

AZN.UK

10,326

-0.41%↓

GSK

1,423.5

+0.04%↑

AZN.UK

10,326

-0.41%↓

GSK

1,423.5

+0.04%↑

AZN.UK

10,326

-0.41%↓

GSK

1,423.5

+0.04%↑

AZN.UK

10,326

-0.41%↓

GSK

1,423.5

+0.04%↑

Search

Indivior PLC

Open

830 0.12

Overview

Share price change

24h

Current

Min

815

Max

849

Key metrics

By Trading Economics

Income

-19M

47M

Sales

-33M

266M

P/E

Sector Avg

330

54.533

EPS

0.41

Profit margin

17.669

Employees

1,030

EBITDA

-30M

76M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+20.19% upside

Dividends

By Dow Jones

Next Earnings

24 Jul 2025

Market Stats

By TradingEconomics

Market Cap

259M

1.1B

Previous open

829.88

Previous close

830

Indivior PLC Chart

Past performance is not a reliable indicator of future results.

Related News

22 May 2025, 23:48 UTC

Hot Stocks

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22 May 2025, 23:07 UTC

Top News

Fortescue Energy CEO to Resign in Executive Overhaul

22 May 2025, 23:03 UTC

Major Market Movers

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22 May 2025, 23:59 UTC

Market Talk

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22 May 2025, 23:45 UTC

Market Talk

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22 May 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

22 May 2025, 23:23 UTC

Market Talk

Global Energy Roundup: Market Talk

22 May 2025, 23:23 UTC

Market Talk

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22 May 2025, 23:12 UTC

Top News

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22 May 2025, 21:54 UTC

Top News

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22 May 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 May 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 May 2025, 20:46 UTC

Acquisitions, Mergers, Takeovers

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22 May 2025, 20:39 UTC

Earnings

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22 May 2025, 20:36 UTC

Top News

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22 May 2025, 20:36 UTC

Top News
Earnings

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22 May 2025, 20:32 UTC

Top News
Earnings

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 May 2025, 20:27 UTC

Top News

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22 May 2025, 20:20 UTC

Top News

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 May 2025, 20:17 UTC

Top News

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22 May 2025, 20:16 UTC

Earnings

Intchains Group 1Q Rev $18.2M >ICG

22 May 2025, 20:15 UTC

Top News

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 May 2025, 20:08 UTC

Top News
Earnings

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 May 2025, 20:05 UTC

Top News

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22 May 2025, 20:04 UTC

Earnings

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22 May 2025, 20:04 UTC

Earnings

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22 May 2025, 20:01 UTC

Earnings

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22 May 2025, 20:01 UTC

Earnings

Workday 1Q Net $68M >WDAY

22 May 2025, 20:01 UTC

Earnings

Workday 1Q EPS 25c >WDAY

22 May 2025, 20:01 UTC

Earnings

Workday 1Q Adj EPS $2.23 >WDAY

Peer Comparison

Price change

Indivior PLC Forecast

Price Target

By TipRanks

20.19% upside

12 Months Forecast

Average 1,014.42 GBX  20.19%

High 1,100 GBX

Low 968.247 GBX

Based on 4 Wall Street analysts offering 12 month price targets forIndivior PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.